NCT07012486

Efficacy of Dihydroartemisinin for Treating Female Androgenetic Alopecia

A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Female Androgenetic Alopecia

• Status: Recruiting
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Androgenetic Alopecia (AGA) in female adults. The main question it aims to answer is: • Does DHA increase terminal hair follicles in the vertex area. Researchers will compare oral DHA plus topical minoxidil to topical minoxidil alone in female patients with AGA to see if DHA works to alleviate AGA. Participants will: * Receive oral DHA every day plus topical minoxidil or use topical minoxidil alone for 6 months. * Visit the clinic once every month for checkups and tests.

Conditions

• Androgenetic Alopecia (AGA)

Interventions

Type	Name	Description
DRUG	Oral DHA + Topical minoxidil 5%	DHA 20mg tid po plus daily topical minoxidil 5% for 180 days
DRUG	Topical Minoxidil 5%	Topical minoxidil 5% daily for 180 days

Timeline

• Start date: 2025-06-01
• Primary completion: 2026-05-01
• Completion: 2026-12-01
• First posted: 2025-06-10
• Last updated: 2025-06-10

Locations

1 site across 1 country: China